CTLA4 and myeloid sarcoma: These data support the hypothesis that a reduced sensitivity to the negative and regulatory CTLA-4-mediated signaling could characterize MS patients, distinguishing them from healthy controls, and in particular, the failure of the anergy of hMBP-reactive T cells, which might be associated with a defect in CTLA-4-mediated signaling, could occur in these patients [76].